Olema launched this year’s 75^th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.

Unable to land an academic job and unwilling to work in industry, Ethan Perlstein is using 21st-century tools to bootstrap his rare-disease drug discovery platform. But can he raise a million dollars?

Unable to land an academic job and unwilling to work in industry, Ethan Perlstein is using 21st-century tools to bootstrap his rare-disease drug discovery platform. But can he raise a million dollars?

Start-ups raised a total of $670.3 million across all industries in Q4 2012, just $11.6 million less than in Q3, and 90% of that money went to biopharma companies. Several start-up companies inked deals with Big Pharmas, and there were three acquisitions – two in biopharma and one in the device sector.